Recent developments in hormone delivery systems

American Journal of Obstetrics and Gynecology

Volumn 190, Issue 4 SUPPL., 2004, Pages

  Shulman, Lee P ^a   Nelson, Anita L ^b   Darney, Philip D ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hormonal implants; Levonorgestrel releasing intrauterine contraceptive system; Once a month injectable

Indexed keywords

CONTRACEPTIVE AGENT; COPPER INTRAUTERINE DEVICE; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHYLENE VINYL ACETATE COPOLYMER; ETONOGESTREL; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

ABDOMINAL PAIN; ACNE; ADENOMYOSIS; AMENORRHEA; BACKACHE; BREAKTHROUGH BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEPRESSION; DRUG CONTRAINDICATION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG SELF ADMINISTRATION; DYSMENORRHEA; FEMALE; HEADACHE; HEART INFARCTION; HORMONAL CONTRACEPTION; HUMAN; HYPERTENSION; INTRAUTERINE CONTRACEPTIVE DEVICE; KIDNEY HYPOPLASIA; LIBIDO DISORDER; MASTALGIA; MENORRHAGIA; MENSTRUATION DISORDER; METRORRHAGIA; NAUSEA; NERVOUSNESS; PATIENT ATTITUDE; PATIENT SATISFACTION; PRIORITY JOURNAL; PULMONARY ARTERY HYPERPLASIA; REVIEW; SIDE EFFECT; SINUSITIS; SKIN DISEASE; SYSTEMATIC REVIEW; TERATOGENICITY; UPPER RESPIRATORY TRACT INFECTION; VAGINA BLEEDING; VAGINITIS; WEIGHT GAIN;

EID: 2342421095     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2004.01.064     Document Type: Article

References (53)

1. Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect 1998;30:24-29, 46.
2. Ortho Pharmaceutical Corp. 1998 Annual Birth Control Study. Raritan, NJ: Ortho Pharmaceutical Corp; 1998.
3. Hatcher RA, Stewart F, Trussell J, et al. Contraceptive technology 1990-1992. New York: Irvington Publishers; 1994.
4. Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999;31:64-72.
5. Hillard PJA. The patient's reaction to side effects of oral contraceptives. Am J Obstet Gynecol 1989;161:1412-5.
6. Kaunitz AM. Injectable contraception. In: Sciarra JJ, editor. Gynecology and obstetrics. New York: Lippincott, Williams and Wilkins; 1999. p. 1-10.
7. Garceau RJ, Wajszczuk CJ, Kaunitz AM. Lunelle Study Group. Bleeding patterns of women using Lunelle monthly contraceptive injections (medroxyprogesterone acetate and estradiol cypionate injectable suspension) compared with those of women using OrthoNovum 7/7/7 (norethindrone/ethinyl estradiol triphasic) or other oral contraceptives. Contraception 2000;62:289-95.
8. Eilers GM, Swanson TK. Women's satisfaction with Norplant as compared with oral contraceptives. J Fam Pract 1994;38:596-600.
9. Aedo AR, Landgren BM, Johannisson E, Diczfalusy E. Pharmacokinetic and pharmacodynamic investigations with monthly injectable contraceptive preparations. Contraception 1985;31:453-69.
10. Coutinho EM, de Souza JC. Contraception control by monthly injections of medroxyprogesterone suspension and a long-acting estrogen. J Reprod Fertil 1968;15:209-14.
11. World Health Organization (WHO) Task Force on Research on Introduction and Transfer of Technologies for Fertility Regulation, Special Programme of research, Development and Research Training in Human Reproduction. A multicentered phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection, I: contraceptive efficacy and side effects. Contraception 1988;37:1-20.
12. Hall PE. New once-a-month injectable contraceptives, with particular reference to Cyclofem/Cyclo-Provera. Int J Gynecol Obstet 1998;62(suppl 1):S43-56.
13. Kaunitz AM, Garceau RJ, Cromie MA, the LUNELLE Study Group. Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Contraception 1999;60:179-87.
14. Shulman LP, Oleen-Burkey M, Willke RJ. Patient acceptability and satisfaction with Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension). Contraception 1999;60:215-22.
15. Rosenfeld JA, Zahorik PM, Saint W, Murphy G. Women's satisfaction with birth control. J Fam Pract 1993;36:169-73.
16. Shulman LP. Compliance and contraception: sharing responsibility for improving outcomes. Female Patient 1997:16-20.
17. Bahamondes L, Lavin P, Ojeda G, Petta C, Diaz J, Maradiegue E, et al. Return to fertility after discontinuation of once-a-month injectable contraceptive Cyclofem. Contraception 1997;55:307-10.
18. Nilsson CG, Lahteenmaki P, Luukkainen T. Patterns of ovulation and bleeding with a low levonorgestrel-releasing intrauterine device. Contraception 1980;21:155-64.
19. Andersson K. The levonorgestrel intrauterine system: more than a contraceptive. Eur J Contracept Reprod Health Care 2001;6(Suppl 1):15-22.
20. Mirena (LNG IUS) [package insert]. Montvale, NJ: Berlex Laboratories, Inc; 2000.
21. French RS, Cowan FM, Mansour D, Higgins JP, Robinson A, Procter T, et al. Levonorgestrel-releasing (20 microgram/day) intrauterine systems (Mirena) compared with other methods of reversible contraceptives. BJOG 2000;107:1218-25.
22. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol 1982;17:529-36.
23. Critchley HO, Wang H, Jones RL, Kelly RW, Drudy TA, Gebbie AE, et al. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery. Hum Reprod 1998;13:1218-24.
24. Mandelin E, Koistinen H, Koistinen R, Affandi B, Seppala M. Levonorgestrel-releasing intrauterine device-wearing women express contraceptive glycodelin A in endometrium during midcycle: another contraceptive mechanism? Hum Reprod 1997;12:2671-5.
25. Barbosa I, Olsson SE, Odlind V, Goncalves T, Coutinho E. Ovarian function after seven years' use of a levonorgestrel IUD. Adv Contracept 1995;11:85-95.
26. Grimes D, editor. Increasing access to IUDs. The Contraception Report 1998;9.
27. Sivin I. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol 1991;77:960-1.
28. Sivin I. Dose- and age-dependent ectopic pregnancy risks with intrauterine contraception. Obstet Gynecol 1991;78:291-8.
29. Luukkainen T, Allonen H, Haukkamaa M, Holma P, Pyorala T, Terho J, et al. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study. Contraception 1987;36:169-79.
30. Jensen JT. Noncontraceptive applications of the levonorgestrel intrauterine system. Curr Womens Health Rep 2002;2:417-22.
31. Ronnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system: a follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand 1999;78:716-21.
32. Jarvela I, Tekay A, Jouppila P. The effect of a levonorgestrel-releasing intrauterine system on uterine artery blood flow, hormone concentrations and ovarian cyst formation in fertile women. Hum Reprod 1998;13:3379-83.
33. Luukkainen T, Pakarinen P, Toivonen J. Progestin-releasing intrauterine systems. Semin Reprod Med 2001;19:355-63.
34. Andersson K, Batar I, Rybo G. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T. Contraception 1992;46:575-84.
35. Luukkainen T, Allonen H, Haukkamaa M, Lahteenmaki P, Nilsson CG, Toivonen J. Five years' experience with levonorgestrel-releasing IUDs. Contraception 1986;5:139-48.
36. Backman T, Huhtala S, Blom T, Luoto R, Rauramo I, Koskenvuo M. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users. BJOG 2000;107:335-9.
37. Ikomi A, Pepra EF. Efficacy of the levonorgestrel intrauterine system in treating menorrhagia: actualities and ambiguities. J Fam Plann Reprod Health Care 2002;28:99-100.
38. Lahteenmaki P, Haukkamaa M, Puolakka J, Riikonen U, Sainio S, Suvisaari J, et al. Open randomized study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. BMJ 1998;316:1122-6.
39. Nagrani R, Bowen-Simpkins P, Barrington JW. Can the levonorgestrel intrauterine system replace surgical treatment for the management of menorrhagia? BJOG 2002;109:345-7.
40. Vercellini P, Aimi G, Panazza S, De Giorgi O, Pesole A, Crosignani PG. A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study. Fertil Steril 1999;72:505-8.
41. Varila E, Wahlstrom T, Rauramo I. A 5-year follow-up study on the use of levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001;76:969-73.
42. Raudaskoski T, Tapanainen J, Tomas E, Luotola H, Pekonen F, Ronni-Sivula H, et al. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG 2002;109:136-44.
43. Nilsson CG, Luukkainen T, Diaz J, Allonen H. Intrauterine contraception with levonorgestrel: a comparative randomised clinical performance study. Lancet 1981;1(Pt 1):577-80.
44. Darney PD. Implantable contraception. Eur J Contracept Reprod Health Care 2000;5(suppl 2):2.
45. Meckstroth KR, Darney PD. Implant contraception. Semin Reprod Med 2001;19:339-54.
46. Zheng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF. A randomized multicenter study comparing the efficacy and bleeding pattern of a single rod (Implanon) and a six capsule (Norplant) hormone contraceptive implant. Contraception 1999;60:1-8.
47. Sivin I, Campodonico I, Kiriwat O, Holma P, Diaz S, Wan L, et al. The performance of levonorgestrel rod and Norplant contraceptive implants: a 5-year randomized study. Hum Reprod 1998;13:3371-8.
48. Huber J, Wenzl R. Pharmacokinetics of Implanon: an integrated analysis. Contraception 1998;58:85S.
49. Mascarenhas L. Insertion and removal of Implanon. Contraception 1998;58(Suppl 6):79S-83S.
50. Bennink HJ. The pharmacokinetics and pharmacodynamics of Implanon, a single-rod etonorgestrel contraceptive implant. Eur J Contracept Reprod Health Care 2000;5(Suppl 2):12-20.
51. Croxatto HB, Makarainen L. The pharmacodynamics and efficacy of Implanon: an overview of the data. Contraception 1998;58:91S.
52. Croxatto HB. Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care 2000;5(Suppl 2):21-8.
53. Affandi B. An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon. Contraception 1998;58(Suppl 6):99S-107S.